Following the discovery in 1994 and 1995 that use of the glycopeptide antim
icrobial avoparcin for growth promotion was associated with the occurrence
of vancomycin resistant Enterococcus faecium in food animals and in food, t
he Danish Minister of Food, Agriculture and Fisheries banned the use of avo
parcin in May 1995. The ban was later extended by the European Commission t
o include all EU member states. In May 1999, the EU Scientific Steering Com
mittee recommended that use for growth promotion of antimicrobials, which a
re or may be used in human or veterinary medicine should be phased out as s
oon as possible and ultimately abolished. During the first half of the 1990
s the consumption of tetracyclines, mainly in pig production, increased mar
kedly. This was countered by severely reducing through legal means the fina
ncial enticement for veterinarians to prescribe medicines and by restrictin
g the availability of tetracycline as non-registered speciality products. T
he focus on consumption of antimicrobials and on resistance prompted a numb
er of initiatives by Danish authorities to limit the increase in antimicrob
ial resistance. One such initiative was the implementation of an integrated
programme (DANMAP), which monitors resistance among bacteria from food ani
mals, food and humans. A programme to monitor all use of prescription medic
ine in food animals at the herd level is presently being implemented. Anoth
er initiative was the elaboration of a series of practical recommendations
to veterinarians on the prudent use of antimicrobials in order to reduce th
e development of resistance without compromising therapeutic efficacy. Our
experience with avoparcin shows that a restrictive policy on the use of ant
imicrobials can curb the development of resistance. However, the occurrence
and persistence of specific resistance phenotypes is the end-result of com
plex interactions of, among others, antimicrobial co-selection, clonal spre
ad of resistant strains and Various herd management factors.